SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported)
January 25, 2013
INNOVUS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in
(State or Other Jurisdiction of Incorporation)
|(Commission File Number)
||(IRS Employer Identification No.)|
4275 Executive Square, Suite 207, San
Diego CA, 92037
(Address of Principal Executive Offices) (Zip
(Registrant's Telephone Number, Including
80 W. Sierra Madre Blvd., #392, Sierra
Madre, CA 91024
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications
pursuant to Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement.
See disclosure in Item 2.03 below regarding amendment
of outstanding 8% convertible debentures issued January 2012.
Item 2.03 Creation of Direct
Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
On January 29, 2013, we agreed with each holder of
outstanding 8% convertible debentures issued in January 2012, to extend the maturity date of such debentures to January 13, 2014.
The outstanding notes have an aggregate principal amount of $162,668. The other terms of these convertible debentures are described
in our Form 10-Q for the period ended March 31, 2012. Such terms provide that such debentures will be payable upon completion of
a financing of a minimum of $4 million if such completion occurs before the maturity date. Three of these debentures are held by
directors Vivian Liu ($50,000 in principal amount), Henry Esber ($13,000 in principal amount) and Ziad Mirza ($5,000 in principal
These amendments did not affect the 8% convertible
debentures issued in January 2013 to Dr. Esber and Bassam Damaj, our President and Chief Executive Officer.
Item 5.02 Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 25, 2013, Ramon Jadra informed us that
due to other professional commitments, he needed to revoke his acceptance of the appointment to our Board of Directors. His resignation
was effective on January 25, 2013. Mr. Jadra’s resignation was not due to any disagreement with our company on any matter
related to our company’s operations, policies or practices.
Item 8.01 Other Events.
On January 28, 2013, we paid in full the principal
and accrued interest on the $50,000 promissory note to Dawson James Securities, Inc. described in our Form 10-K for the year ended
December 31, 2011.
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 30, 2013
By: /s/ Bassam Damaj
Name: Bassam Damaj
Title: President and Chief Executive Officer